FDA awards grants for Clinical Trials on Rare Diseases

The U.S Food and Drug Administration on October 8, 2019, announced a total of 12 new grants amounting to a total of more than $15 million which will be distributed over the next 4 years to perform the Clinical Trials on Rare diseases. The grant will be used to facilitate the clinical development of drugs, biologics, medical  devices and medical foods for the treatment of rare diseases that include Duchenne Muscular Dystrophy, sickle cell disease, Fanconi anemia and some others. These grants were awarded to the principal investigators from academics and industry across the country through the Orphan Products ClinicalTrials Grants Program of FDA.

These approved grants are mainly focused on the advancement of the product development to meet the need of patients suffering from various rare diseases, with emphasis on those affecting children and cancers. These newly awarded grants are intended to accelerate the clinical approval of products for effective and efficient treatment of rare diseases as well as to provide essential clinical data for the development of thee products.

In a total, FDA received 89 clinical trial grant applications for review and evaluation by more than 100 scientific experts from industry and academia fraternity. In a total of 12 awarded grants, more than half of the awards will be focusing on the study of targeting a variety of rare diseases affecting children and having a high risk of life-threatening conditions. whereas, two-thirds of the new awards are expected  to fund clinical studies of medical products involving in treatment of various rare cancers such as genetically engineered virus therapy and novel drug delivery system, which, ultimately may eliminate current barriers to drug delivery that patients come across during treatment.
Source: https://bit.ly/33patKF

Know more about the recent happenings in the Pharma sciences and Clinical research. Join us at the European Congress on Pharmaceutical Sciences


Keywords:
Pharma Conferences | Pharmaceutical Conferences | Clinical Trials Congress | Pharmacology Congress

Comments

Post a Comment

Popular posts from this blog

Announcement: Euro Pharma 2020

Image
The Pharmaceutical industry over the years has been changing rapidly with the advent of various technologies. This has indeed helped us in coming up with some of the great healthcare solutions for the current and future generations. However, at this pace of the research and development, it becomes essential for researchers and industries to share their research findings to prevent the process of spinning the wheel again and also to address the challenges encountered during the process. We at the Euro Pharma series of events, try together the subject experts to tackle these issues to provide better healthcare services for the future generation. After successfully hosting the 3 rd series of the Europharma event in Rome, Italy, we are glad to announce that the next event, “4 th World Congress on Pharma and Pharmaceutical Sciences” is now scheduled to be held at Frankfurt, Germany on March 16-17, 2020. The event is planned around the theme of Shaping the Future of Healt...
Read more

New Genomic Method for Diagnosis of Rare Genetic Diseases

A team of scientists has developed a new genomic method to detect the cause of rare genetic diseases . The method, called Analysis of expression Variation-Dosage Outlier Test, and abbreviated as ANEVA-DOT, makes use of gene transcription data to detect differences in the activity levels of maternal and paternal alleles of genes, which people acquire from their parents. It compares activity levels of maternal and paternal alleles across the genome and detects when the activity of an allele goes beyond the normal range to become a viable cause of a certain disease. Usually, many rare genetic diseases develop from DNA mutations that affect only a single allele of a gene. The method uses the calculation of a healthy range of differences in maternal allele and paternal allele activity for every gene from gene transcription data. Thus, it can be used to identify genes with abnormal expression levels in alleles. Typically, standard methods of sequencing genes and their transcripts are...
Read more